Market Overview

Morgan Stanley Remains Bullish On Comcast

Morgan Stanley Remains Bullish On Comcast

Comcast Corporation (NASDAQ: CMCSA) remains worth watching.

The Analyst

Morgan Stanley’s Benjamin Swinburne reiterated an Overweight rating on Comcast with a $46 price target.

The Thesis

Swinburne believes a continuing expansion in broadband will offset declines in video. And, the company’s Britain-based Sky Network should help drive EBITDA growth, with lower costs for televising the English Premier League soccer league in the next two years.

But underlying everything is the fundamental core business, he said.

Swinburne noted that as Comcast pursued Fox and Sky last year, investors seemed to forget about the fundamental performance of the company’s core cable TV business and its NBC assets.

“Fortunately, the healthy performance of these businesses last year has continued into 2019, and we remain confident in our outlook,” Swinburne wrote in a Tuesday note to investors.

Morgan Stanley believes Comcast’s NBCU should benefit from a strong ad market and healthy slates of films in 2019 and 2020.

Swinburne also said Verizon Communications Inc. (NYSE: VZ)'s plans for home 5G service “have had no discernible impact to cable broadband results or expectations, including Comcast.”

Price Action

Comcast traded around $40 per share at time of publication.

Related Links:

Raymond James Raises Comcast Price Target To Reflect Sky Synergies, Broadband Sub Growth

RBC Downgrades Comcast, Charter On Cable Concerns

Photo courtesy of Comcast.

Latest Ratings for CMCSA

Oct 2019Initiates Coverage OnMarket Perform
Oct 2019MaintainsBuy
Sep 2019Initiates Coverage OnBuy

View More Analyst Ratings for CMCSA
View the Latest Analyst Ratings

Posted-In: Benjamin Swinburne Morgan Stanley NBC Sky NetworkAnalyst Color Reiteration Analyst Ratings Best of Benzinga


Related Articles (CMCSA + VZ)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Afternoon Market Update: ADMA Biologics Jumps On FDA Nod For Immunodeficiency Therapy; Evoke Pharma Shares Plummet

Emerald Growth Partners Pre-Qualified For Operations In Michigan